AL003 *

AL003 targets a sialic acid binding Ig-like lectin 3 (SIGLEC 3) that is genetically linked to Alzheimer’s disease.

AL003 is being developed by Alector for the treatment of Alzheimer’s disease and Alector is responsible for the execution of Phase 1 and Phase 2 studies. Following its exercise of an option for a program, AbbVie will be responsible for certain development activities and global commercialization.

Type of Molecule

Biologic

Target

SIGLEC 3

Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted, Approved)
Alzheimer's Disease (AD) n/a
Phase 1